OMERS ADMINISTRATION Corp Invests $1.01 Million in BioNTech SE (NASDAQ:BNTX)

OMERS ADMINISTRATION Corp bought a new stake in shares of BioNTech SE (NASDAQ:BNTX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 8,900 shares of the company's stock, valued at approximately $1,014,000.

A number of other hedge funds have also bought and sold shares of BNTX. Jones Financial Companies Lllp increased its stake in shares of BioNTech by 110.3% in the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock worth $53,000 after acquiring an additional 246 shares during the period. Quintet Private Bank Europe S.A. lifted its holdings in BioNTech by 823.5% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock valued at $88,000 after purchasing an additional 700 shares in the last quarter. Allianz SE purchased a new position in shares of BioNTech in the fourth quarter worth about $90,000. Generali Investments CEE investicni spolecnost a.s. purchased a new position in shares of BioNTech in the fourth quarter worth about $137,000. Finally, AlphaCentric Advisors LLC purchased a new position in shares of BioNTech in the fourth quarter worth about $168,000. Institutional investors and hedge funds own 15.52% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. BMO Capital Markets upped their price target on BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a research note on Tuesday, March 11th. HC Wainwright reiterated a "buy" rating and set a $134.00 price target (down from $145.00) on shares of BioNTech in a research report on Wednesday, May 14th. Morgan Stanley dropped their price target on shares of BioNTech from $140.00 to $132.00 and set an "overweight" rating for the company in a research report on Tuesday, May 6th. Citigroup reiterated a "buy" rating and set a $140.00 price target (down from $145.00) on shares of BioNTech in a research report on Tuesday, May 6th. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $171.44 price target on shares of BioNTech in a research report on Tuesday, March 11th. Three investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $142.08.

BioNTech Stock Up 4.0%

BioNTech stock traded up $3.92 during trading on Tuesday, reaching $101.72. The stock had a trading volume of 1,812,605 shares, compared to its average volume of 935,411. BioNTech SE has a 52-week low of $76.53 and a 52-week high of $131.49. The business has a 50 day moving average price of $97.36 and a 200 day moving average price of $108.72. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The stock has a market cap of $24.45 billion, a PE ratio of -48.44 and a beta of 1.35.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.70. The business had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company's revenue was down 19.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.90 EPS. On average, analysts predict that BioNTech SE will post -3.88 EPS for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.